Home
Articles
Case Studies
White Papers
Events
Research Papers
Media Partnership
Multimedia
Oman Pharmaceutical Products Company, OPP, belonging to the Al Bahja Group announced that it has won its first product approval from the US Federal Drug Administration (FDA).
OPP said it won the FDA approval for its product Neomycin, paving the way for its sale in the US. The development follows the successful audit of OPP’s manufacturing facility by FDA officials recently.
Al Bahja Group Managing Director Sujay Hamlai, said “We are extremely delighted with this approval. It validates our commitment to provide quality medicines at affordable prices.”
Recent Comments